Medication Guide for Tobramycin Inhalation Solution_Cortex

Tobramycin Inhalation Solution is an inhaled antibiotic preparation for bronchopulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis. The drug was developed by the Swiss company Novartis and was approved by the US FDA in 1997. The specification is 300mg/5ml/box. As an aminoglycoside antibiotic, it exerts its therapeutic effect by acting directly on the site of respiratory tract infection, but special attention must be paid to standardized usage and related contraindications.

Dosage Guidelines for Tobramycin Inhalation Solution

Correct use is crucial to reducing the risk of adverse reactions, and patients should take the medication under the guidance of a doctor.

Standard dosage regimen

The recommended dose is 300mg (1 vial) each time, twice a day, with an interval of about 12 hours, for 28 days and then 28 days after discontinuation for a complete cycle. A special Air 360 series mesh atomizer must be used, and each atomization time is about 10-15 minutes. If you miss a dose, you can take it immediately if it is more than 6 hours before the next dose.

Correct usage

Before use, check that the liquid should be a light yellow and clear liquid. Squeeze the entire liquid into the atomizer cup and inhale it through the mouth until no mist is produced. Bronchodilators can be used 15 minutes before nebulization to prevent bronchospasm. Rinse mouth thoroughly after aerosolization to reduce oropharyngeal discomfort.

Drug interaction management

It is prohibited to use this product in combination with powerful diuretics (such as furosemide). Avoid concomitant use with other ototoxic or nephrotoxic drugs. Concomitant use with neuromuscular blockers may potentiate respiratory depression. Inform your doctor of all medications you are taking before use.

Mastering these medication specifications can improve the therapeutic effect. The relevant contraindications will be introduced below.

Contraindications of Tobramycin Inhalation Solution

The use of this drug in some specific circumstances may bring serious risks, and the contraindications need to be strictly observed.

Absolute contraindications

It is prohibited for those allergic to tobramycin or other aminoglycosides. Contraindicated in patients with myasthenia gravis. It is contraindicated for pregnant women as it may cause harm to the fetus. Do not use if the solution is turbid or contains particles.

Relative contraindications

Safety for children under 6 years old has not been established. Use with caution in patients with severe renal insufficiency (creatinine clearance <30ml/min). People with existing hearing loss or vestibular dysfunction should use with caution.

Situations where medication needs to be suspended

Severe allergic reactions require permanent discontinuation of medication. Medication needs to be suspended in the event of moderate to severe ototoxicity or nephrotoxicity. You may need to temporarily stop taking medications for 1-2 weeks before and after surgery.

Understanding these contraindications will help you use medication safely. The following will introduce medication precautions for special groups.

Usage of Tobramycin Inhalation Solution for Special Populations

The use of this drug by different groups of people requires consideration of their physiological characteristics and special risks.

Pediatric patients

Cystic fibrosis patients 6 years and older may use standard doses. Safety for children under 6 years old has not been established and use is not recommended. Prepubertal children need to pay special attention to the effects on growth and development.

Elderly patients

Data on patients over 75 years old are limited and require individualized assessment. Due to possible decrease in renal function, increased monitoring and dose adjustment should be considered. Elderly patients have a higher risk of infection and need to be alert to adverse reactions such as bronchospasm.

Patients with abnormal liver and kidney function

No dosage adjustment is required for patients with mild to moderate hepatic dysfunction. Patients with severe renal insufficiency need to reduce the dose and closely monitor plasma concentrations. Hemodialysis patients should be administered the drug after dialysis.

Pregnant women, lactating women and children should use it with special caution. Elderly patients and those with renal insufficiency need to adjust the dosage. If you experience tinnitus, dizziness, or decreased urine output while taking this medication, you should seek medical attention immediately.